Published in Bioorg Med Chem Lett on March 10, 2010
The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol (2002) 1.76
Expression of chemokine receptor CXCR3 on T cells affects the balance between effector and memory CD8 T-cell generation. Proc Natl Acad Sci U S A (2011) 1.28
Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis. J Immunol (2003) 1.22
Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology (2006) 1.21
Intravital analysis of vascular permeability in mice using two-photon microscopy. Sci Rep (2013) 1.11
In vivo imaging of T-cell motility in the elicitation phase of contact hypersensitivity using two-photon microscopy. J Invest Dermatol (2011) 0.97
PGD2 induces eotaxin-3 via PPARγ from sebocytes: a possible pathogenesis of eosinophilic pustular folliculitis. J Allergy Clin Immunol (2011) 0.89
Prostaglandin E2 increase in pachydermoperiostosis without 15-hydroprostaglandin dehydrogenase mutations. Acta Derm Venereol (2013) 0.89
R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models. Eur J Pharmacol (2004) 0.81
Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 1. Bioorg Med Chem Lett (2009) 0.81
Anti-type II collagen antibody accelerates arthritis via CXCR2-expressing cells in IL-1 receptor antagonist-deficient mice. Eur J Immunol (2007) 0.79
Histamine modulates the responsiveness of keratinocytes to IL-17 and TNF-α through the H1-receptor. J Dermatol Sci (2010) 0.79
Novel p38 mitogen-activated protein kinase inhibitor R-130823 protects cartilage by down-regulating matrix metalloproteinase-1,-13 and prostaglandin E2 production in human chondrocytes. Int Immunopharmacol (2005) 0.79
Novel p38 MAP kinase inhibitor R-130823 suppresses IL-6, IL-8 and MMP-13 production in spheroid culture of human synovial sarcoma cell line SW 982. Immunol Lett (2005) 0.79
Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist. Bioorg Med Chem Lett (2012) 0.77
Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator. J Clin Pharmacol (2008) 0.77
High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol (2011) 0.77
Synthesis and SAR of 1,3-thiazolyl thiophene and pyridine derivatives as potent, orally active and S1P₃-sparing S1P₁ agonists. Bioorg Med Chem Lett (2012) 0.77
Neonatal goiter with congenital thyroid dysfunction in two infants diagnosed by MRI. Pediatr Radiol (2004) 0.75
Oral allergy syndrome complicated with multiple food sensitization detected by specific IgEs. Eur J Dermatol (2012) 0.75
Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 3. Bioorg Med Chem Lett (2010) 0.75
Syntheses of glucose analogues of E5564 as a highly potent anti-sepsis drug candidate. Bioorg Med Chem (2006) 0.75
Skin tape stripping and cheek swab method for a detection of filaggrin. J Dermatol Sci (2013) 0.75
Syntheses of glucose derivatives of E5564-related compounds and their LPS-antagonistic activities. Carbohydr Res (2006) 0.75
Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist. Eur J Med Chem (2012) 0.75
Forty-two-day-old boy with acute idiopathic thrombocytopenic purpura. Pediatr Int (2010) 0.75
PCR-RFLP analysis for S2889X in filaggrin harbors the risk of a typing error. J Dermatol Sci (2012) 0.75